Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences Inc.

< Previous 1 2 3 Next >
News headline image
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Reports Third Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.